This is one of the most important Foundayo data points since the drug was approved. The Phase 3 ACHIEVE-4 trial enrolled more than 2,700 patients across 15 countries and compared once-daily oral Foundayo to insulin glargine in adults with type 2 diabetes who were overweight or obese with elevated cardiovascular risk. Foundayo met the primary MACE-4 non-inferiority endpoint (HR 0.84), showing a 16% relative reduction in the composite of cardiovascular death, heart attack, stroke, and hospitalization for unstable chest pain. More importantly, a pre-planned analysis showed 57% lower all-cause death with Foundayo versus insulin glargine (HR 0.43, p=0.002). At 52 weeks, Foundayo delivered superior A1C reduction and 8.8% body weight loss versus 1.7% weight gain on insulin. These data do two things. First, they clear the cardiovascular safety bar the FDA specifically flagged in its approval letter for the obesity indication. Second, they give Lilly the filing basis for a type 2 diabetes indication, which the company plans to submit under the CNPV by end of Q2 2026. A diabetes label would dramatically expand Foundayo’s addressable market from roughly 40 million U.S. adults with obesity to an additional 37 million with type 2 diabetes.
Top Story: Foundayo Meets CV Safety Bar and Shows 57% Lower Death Risk in Largest Diabetes Trial
What Happened: Lilly announced positive topline results from the Phase 3 ACHIEVE-4 trial on April 16. The trial is the largest and longest study of Foundayo in type 2 diabetes, enrolling more than 2,700 participants across 15 countries and comparing once-daily oral Foundayo to insulin glargine in adults with type 2 diabetes and obesity or overweight at increased cardiovascular risk.
The Data Package
Primary endpoint (MACE-4): Foundayo met non-inferiority versus insulin glargine. The hazard ratio was 0.84 (95% CI 0.59 to 1.20). MACE-4 is a composite of cardiovascular death, heart attack, stroke, and hospitalization for unstable chest pain. The 0.84 hazard ratio represents a 16% relative reduction in major adverse cardiovascular events, though the confidence interval crosses 1.0, meaning the result demonstrates non-inferiority but does not establish superiority for MACE-4 as a composite.
All-cause mortality: A pre-planned analysis showed 57% lower risk of death with Foundayo versus insulin glargine. The hazard ratio was 0.43 (95% CI 0.25 to 0.75, nominal p=0.002). The confidence interval does not cross 1.0, meaning the result is statistically significant at the nominal level.
A1C at 52 weeks: Treatment difference of 0.66 percentage points favoring Foundayo (reduction of 1.6% versus 1.0% with insulin glargine). Foundayo was statistically superior to insulin on glycemic control.
Body weight at 52 weeks: Foundayo patients lost 8.8% body weight (8.1 kg). Insulin glargine patients gained 1.7%. The weight divergence is substantial—in a diabetes trial comparing an oral GLP-1 to insulin, Foundayo produced nearly 10 percentage points of weight separation.
Durability: A1C and weight improvements persisted through 104 weeks, demonstrating that the metabolic benefits of Foundayo are maintained over two years of treatment.
Why the Cardiovascular Safety Data Matters
The FDA’s approval letter for Foundayo’s obesity indication specifically flagged concerns around MACE, drug-induced liver injury, delayed stomach emptying, and long-term thyroid cancer risk. ACHIEVE-4 addresses the MACE concern directly. The 0.84 hazard ratio on the composite cardiovascular endpoint demonstrates that Foundayo is at least as safe as insulin glargine—the most widely prescribed basal insulin in the world—in a high-cardiovascular-risk population.
This is the data Lilly needed. The obesity approval came under the CNPV program in 50 days, faster than anyone expected, but the cardiovascular safety question remained open. ACHIEVE-4 closes that question with a dataset large enough and long enough to be definitive for non-inferiority.
The Mortality Signal: What It Means and What It Does Not
The 57% lower all-cause death (HR 0.43) is the headline number, and it requires careful interpretation.
What it means: In a trial of more than 2,700 patients, significantly fewer people died on Foundayo than on insulin glargine. The hazard ratio of 0.43 and the confidence interval (0.25 to 0.75) do not cross 1.0. The p-value of 0.002 is well below conventional significance thresholds.
What it does not mean: This was a pre-planned exploratory analysis, not the primary endpoint. ACHIEVE-4 was designed and powered for MACE-4 non-inferiority, not for mortality superiority. The absolute number of deaths was likely small—typical for a 2,700-patient trial over 104 weeks—which means the hazard ratio is less robust than it would be in a larger, dedicated cardiovascular outcomes trial. The wide confidence interval (0.25 to 0.75) reflects this uncertainty.
A dedicated cardiovascular outcomes trial with mortality as a primary or key secondary endpoint would need to enroll substantially more patients to confirm this signal with the statistical rigor required for an FDA-approved label claim. Whether Lilly pursues such a trial is an open strategic question that will likely be addressed on the April 30 earnings call.
The Diabetes Filing: Expanding the Addressable Market
Lilly plans to submit Foundayo for type 2 diabetes under the CNPV by end of Q2 2026. Foundayo is currently approved for obesity and overweight with at least one weight-related comorbidity. That addressable market is roughly 40 million U.S. adults. Adding a type 2 diabetes indication opens an additional approximately 37 million Americans with T2D.
The oral formulation is the key differentiator in the diabetes market. Many patients with type 2 diabetes resist starting injectable therapy despite clinical need—needle aversion, lifestyle disruption, and the psychological burden of injecting daily or weekly create significant barriers to treatment initiation. An oral daily pill with no food or water restrictions removes those barriers entirely.
If the diabetes label is approved, Foundayo would compete directly with oral Wegovy (semaglutide, which requires a 30-minute fasting window) and Rybelsus (oral semaglutide for T2D) in the oral segment, and with the full GLP-1 injectable market in the broader type 2 diabetes landscape. The ACHIEVE-4 data package—superior A1C reduction, 8.8% weight loss, cardiovascular safety, and the mortality signal—gives Lilly a compelling case for the diabetes indication.
Filing under the CNPV means the review could potentially be accelerated in the same way the obesity indication was, though the FDA’s approach to repeat CNPV filings for the same molecule has not been tested.
Foundayo Is Already Being Evaluated Across Additional Indications
Beyond obesity and the upcoming diabetes filing, Foundayo is being evaluated across multiple additional indications including obstructive sleep apnea, osteoarthritis, hypertension, peripheral artery disease, and stress urinary incontinence. Each of these represents a comorbidity commonly associated with obesity and type 2 diabetes, where the weight loss and metabolic improvements delivered by GLP-1 therapy could address the underlying driver of the condition rather than treating symptoms alone. If Foundayo accumulates positive data across several of these indications over the next two to three years, it could become the most broadly indicated oral medication in metabolic medicine—a single pill addressing obesity, diabetes, cardiovascular risk, and multiple comorbidities simultaneously.
Our Pro brief analyzes what the mortality signal means and does not mean, how the diabetes label expansion changes the revenue math for Foundayo, and how ACHIEVE-4 positions Foundayo competitively against oral Wegovy in the oral GLP-1 segment. [Details below.]
What to Watch
The Lilly Q1 earnings call on April 30 is the most anticipated report of the quarter. Expect commentary on the Foundayo launch trajectory, ACHIEVE-4 interpretation, the diabetes filing timeline, whether Lilly will pursue a dedicated cardiovascular outcomes trial, and how the company is managing four simultaneous M&A integrations (Kelonia, CrossBridge Bio, Orna, Centessa). The diabetes filing itself—targeted by end of Q2—will be the next regulatory catalyst.
Corporate Developments
Tortugas Neuroscience Debuts with $106M and Four Clinical CNS Programs
Tortugas Neuroscience emerged from stealth on Tuesday with $106 million in funding (seed plus Series A) led by Cure Ventures, Column Group, and AN Venture Partners. CEO Jeff Jonas previously built Sage Therapeutics from startup to marketed product over a decade before stepping down in 2023. The Framingham, Massachusetts-based biotech has four clinical-stage programs licensed from Japan’s Eisai and China’s Hansoh, all small molecules targeting what Jonas described as “derisked mechanisms of action” in central nervous system disorders. Jonas told BioPharma Dive the drugs offer “a rare combination of validated mechanisms and a long patent life.”
Why This Matters: Tortugas follows the same template that produced Kailera ($625 million IPO), Beeline ($300 million Series A), and other recent biotech launches: license clinical-stage assets from established pharma companies, bring in a proven CEO with a track record of value creation, and fund through late-stage development with a single large financing. The CNS space has seen renewed investor interest after years of underinvestment, and Jonas’s Sage track record gives Tortugas immediate credibility with both investors and clinical development partners. The licensing model—acquiring assets from Eisai and Hansoh rather than building from scratch—compresses the timeline from company formation to clinical data, avoiding the five-to-seven-year preclinical journey that traditional biotech startups face.
The Week in Review
This was another week of extraordinary density:
April 16 (Wednesday): Lilly reported ACHIEVE-4 Phase 3 results. Foundayo met CV safety non-inferiority (HR 0.84) and showed 57% lower all-cause death versus insulin glargine (HR 0.43, p=0.002). Diabetes filing targeted by end of Q2 under CNPV.
April 20 (Sunday/Monday): Lilly announced Kelonia acquisition for up to $7 billion ($3.25 billion upfront). Second in vivo CAR-T deal of 2026.
April 21 (Monday): Revolution Medicines presented AACR data: daraxonrasib plus chemotherapy achieved 58% ORR in first-line PDAC (n=40). Monotherapy 47% ORR. RM-055 next-gen catalytic inhibitor preclinical data unveiled. Full Phase 3 data secured ASCO plenary slot (May 31). Merck’s Idvynso approved for HIV a week ahead of PDUFA. Tortugas Neuroscience debuted with $106 million.
April 22 (Tuesday): CMS shelved BALANCE program after CVS/UnitedHealth pushback. Bridge extended through December 2027. Lilly acquired CrossBridge Bio for up to $300 million (dual-payload ADC). Biogen consolidated felzartamab rights for $850 million. J&J beat Q1 estimates with $15 billion-plus in drug sales.
Strategic Themes
1. ACHIEVE-4 Closes the Cardiovascular Safety Question and Opens the Diabetes Market
The FDA flagged cardiovascular safety as a concern in Foundayo’s obesity approval. ACHIEVE-4 addresses that concern with a 0.84 hazard ratio on MACE-4 in a high-risk population—a clean non-inferiority result that establishes Foundayo’s cardiovascular profile as at least comparable to insulin glargine. With this data in hand, Lilly can pursue the diabetes indication with confidence. The filing under CNPV by end of Q2 could potentially yield an accelerated review, expanding the label from obesity into a market of 37 million additional American patients.
2. The Mortality Signal Is Real but Requires Confirmation
A 57% reduction in all-cause death is an extraordinary finding. The statistical significance (p=0.002) and the confidence interval that does not cross 1.0 make it a genuine signal, not a statistical artifact. But the pre-planned exploratory nature of the analysis and the relatively small trial size (2,700 patients) mean the result needs confirmation in a larger trial before it can support a label claim. The strategic decision for Lilly—whether to invest in a dedicated cardiovascular outcomes trial powered for mortality—will define Foundayo’s long-term competitive positioning against injectable GLP-1s that already carry cardiovascular risk reduction claims.
3. The Diabetes Label Would Make Foundayo the Most Broadly Indicated Oral GLP-1
Foundayo is already approved for obesity. A diabetes approval would make it the first oral small-molecule GLP-1 with both obesity and type 2 diabetes indications—covering the two largest metabolic disease populations with a single pill. Oral Wegovy is approved for obesity but not type 2 diabetes (Rybelsus carries the T2D label for the semaglutide molecule). The dual indication would give Foundayo a prescribing advantage for the substantial population of patients who have both obesity and diabetes, allowing physicians to address both conditions with one medication rather than managing separate prescriptions.
4. Lilly Earnings on April 30 Will Be the Most Important Pharma Report of the Quarter
The April 30 earnings call brings together every major Lilly narrative: Foundayo launch trajectory, ACHIEVE-4 interpretation, the diabetes filing timeline, multiple simultaneous M&A integrations, Zepbound/Mounjaro growth, tariff positioning, and the broader metabolic competitive landscape. No other earnings call this quarter combines the number of catalysts, strategic decisions, and competitive dynamics that Lilly’s will address.
Frequently Asked Questions
What is ACHIEVE-4?
The largest and longest Phase 3 trial of Foundayo in type 2 diabetes. It enrolled more than 2,700 patients across 15 countries and compared once-daily oral Foundayo to insulin glargine in adults with T2D who were overweight or obese with elevated cardiovascular risk. The trial ran for 104 weeks.
What did the cardiovascular safety data show?
Foundayo met non-inferiority versus insulin glargine on the primary MACE-4 endpoint (HR 0.84, 95% CI 0.59 to 1.20). The composite includes cardiovascular death, heart attack, stroke, and hospitalization for unstable chest pain. The result confirms that Foundayo is at least as cardiovascularly safe as the most widely prescribed basal insulin.
What does the 57% lower death risk mean?
A pre-planned exploratory analysis showed 57% lower all-cause death with Foundayo versus insulin glargine (HR 0.43, 95% CI 0.25 to 0.75, p=0.002). The result is statistically significant but was not the primary endpoint. The trial was designed for MACE-4 non-inferiority, not mortality superiority. Confirmation in a larger dedicated cardiovascular outcomes trial would be needed for a label claim.
How did Foundayo perform on diabetes control and weight?
At 52 weeks, Foundayo delivered a treatment difference of 0.66 percentage points in A1C reduction versus insulin glargine (1.6% versus 1.0%). Foundayo patients lost 8.8% body weight (8.1 kg) while insulin patients gained 1.7%. Both improvements persisted through 104 weeks.
When will Lilly file for the diabetes indication?
Lilly plans to submit Foundayo for type 2 diabetes under the CNPV by end of Q2 2026. If accepted and reviewed on a similar timeline to the obesity approval (50 days), a diabetes label could arrive in late 2026 or early 2027.
How would a diabetes label change Foundayo’s market?
The obesity label covers roughly 40 million U.S. adults. Adding type 2 diabetes opens an additional approximately 37 million Americans. Many T2D patients resist injectable therapy, and an oral pill with no food or water restrictions directly addresses that barrier. Foundayo would become the first oral small-molecule GLP-1 with both obesity and diabetes indications.
What is Tortugas Neuroscience?
A new CNS-focused biotech launched with $106 million in funding, four clinical-stage programs licensed from Eisai and Hansoh, and ex-Sage Therapeutics CEO Jeff Jonas at the helm. The company targets validated mechanisms in central nervous system disorders with small molecules.
What should investors watch at Lilly’s April 30 earnings?
Foundayo launch trajectory data (Weeks 1 through 3 TRx numbers), ACHIEVE-4 commentary including whether Lilly will pursue a dedicated cardiovascular outcomes trial, the diabetes filing timeline, M&A integration updates across four simultaneous deals, Zepbound/Mounjaro growth, and Section 232 tariff positioning.
BioMed Nexus Pro — What Institutional Subscribers Are Reading Today
ACHIEVE-4 Deep Dive: The Mortality Signal. We analyze what the 57% all-cause death reduction means, what it does not mean, why the pre-planned exploratory designation matters, and how the wide confidence interval affects interpretation. If you are modeling Foundayo’s long-term competitive position, this is the clinical framework that determines whether a dedicated cardiovascular outcomes trial is necessary.
Diabetes Label Expansion: The Revenue Math. We model how adding 37 million T2D patients to the addressable market changes peak sales estimates, assess the competitive positioning against Rybelsus and oral Wegovy in the oral segment, and frame the dual-indication advantage for the overlapping obesity/diabetes population.
Lilly Q1 Earnings Preview: The Five Numbers That Matter. We lay out the data points that will define the April 30 call—Foundayo launch trajectory, Zepbound/Mounjaro growth, ACHIEVE-4 strategic decisions, M&A integration updates, and tariff margin impact.
Plus: Foundayo diabetes filing timeline assessment, ASCO plenary preview, Medicare Bridge enrollment projections, and the updated catalyst calendar through H2 2026.
About BioMed Nexus
BioMed Nexus delivers institutional-grade intelligence to biotech and pharma executives, investors, and clinicians. Our daily briefings and deep-dive analyses cut through the noise to deliver the strategic insights that drive better decision-making in the life sciences.
Subscribe to receive daily updates and gain access to BioMed Nexus Pro institutional intelligence briefs.
